Missouri Trust & Investment Co Has $1.37 Million Holdings in Pfizer Inc. (NYSE:PFE)

Missouri Trust & Investment Co increased its position in shares of Pfizer Inc. (NYSE:PFE) by 3.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,757 shares of the biopharmaceutical company’s stock after acquiring an additional 1,801 shares during the quarter. Missouri Trust & Investment Co’s holdings in Pfizer were worth $1,373,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Bourgeon Capital Management LLC boosted its stake in shares of Pfizer by 610.3% during the 4th quarter. Bourgeon Capital Management LLC now owns 418,658 shares of the biopharmaceutical company’s stock valued at $11,107,000 after buying an additional 359,721 shares during the period. Octavia Wealth Advisors LLC grew its stake in Pfizer by 49.3% in the fourth quarter. Octavia Wealth Advisors LLC now owns 22,159 shares of the biopharmaceutical company’s stock valued at $588,000 after purchasing an additional 7,319 shares in the last quarter. Fort Washington Investment Advisors Inc. OH increased its position in Pfizer by 1.4% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,629,388 shares of the biopharmaceutical company’s stock worth $43,228,000 after purchasing an additional 22,562 shares during the last quarter. JBGlobal.com LLC bought a new stake in shares of Pfizer in the 4th quarter valued at approximately $362,000. Finally, Chesley Taft & Associates LLC increased its holdings in Pfizer by 2.6% in the fourth quarter. Chesley Taft & Associates LLC now owns 152,440 shares of the biopharmaceutical company’s stock worth $4,044,000 after buying an additional 3,833 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent research reports. Bank of America restated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Citigroup assumed coverage on Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 price target for the company. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Finally, Sanford C. Bernstein initiated coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Price Performance

Shares of PFE stock opened at $26.63 on Wednesday. The company has a market capitalization of $150.89 billion, a P/E ratio of 35.98, a P/E/G ratio of 0.63 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a 50 day moving average of $26.08 and a two-hundred day moving average of $27.98.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. As a group, equities analysts expect that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.46%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.